Bicycle Therapeutics Investor Presentation • May 2025 Forward-looking statements Bicycle® molecules are short peptides chemically constrained with a central scaffold that can induce diverse structures Scaffold Chemical modification with scaffold Short linear peptide + Bicycle® molecule This presentation may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "aims," "antici ...

UL SOLUTIONS INC. Disclaimer This presentation and related discussion are being presented by UL Solutions ("UL Solutions," the "Company," "we," "us" and "our") solely for informational purposes. This presentation and accompanying statements contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation and related discussion may be forward-looking statements. These includ ...

Company Overview - Gyre Therapeutics is a pioneering fibrosis treatment company with a track record of success, including being the first to receive IPF treatment approval (pirfenidone) in China in 2011[7] - The company has maintained a leading IPF market share in China for 10 consecutive years, with approximately 50% overall market share and over 90% share in pirfenidone in 2024[7] - Gyre Therapeutics has approximately 600 dedicated global employees, including around 400 in commercial teams across China and the U S and about 70 focused on R&D[7] - In 2024, Gyre Therapeutics achieved revenue of $105 8 million[8] Hydronidone (F351) Development - Hydronidone (F351) is Gyre's lead asset with the potential to be a first-in-class therapy for CHB-related liver fibrosis, addressing a significant unmet medical need in China, and is expected to initiate a Phase 2 trial in the U S for the treatment of MASH-associated liver fibrosis[11] - In a Phase 2 trial, Hydronidone demonstrated significant fibrosis improvement, with 54 8% of patients in the combined Hydronidone groups showing ≥1 stage fibrosis improvement at Week 52, compared to 25 6% in the placebo group[17] - The U S MASH fibrosis market is estimated to be 7 2 times larger than the CHB fibrosis market[24] Strategic Acquisitions and Future Outlook - Gyre acquired Nintedanib and Avatrombopag in 2024 to strengthen its pirfenidone franchise and prepare for the potential future launch of Hydronidone[45] - The company forecasts 2025 sales of $118 million to $128 million[45] - Gyre expects to submit a New Drug Application (NDA) for Hydronidone in Q2 2025, with NMPA approval anticipated in 2026[53]

Financial Performance - The company's total assets reached $1.6 billion as of June 30, 2024 [12] - Net income for the second quarter of 2024 was $6.786 million, a 1.9% increase compared to $6.660 million in the second quarter of 2023 [80] - Net interest income for the second quarter of 2024 increased by 6.8% to $18.405 million from $17.239 million in the second quarter of 2023 [80] - The net interest margin for 2023 was 4.71%, driven by higher rates and strategic investments [30] - In 2023, net income increased by 12.6% to $29.776 million [82] Deposits and Loans - As of June 30, 2024, non-interest-bearing deposits accounted for 51% of total deposits [45] - The average interest-bearing deposit rate was 0.84% for the three months ended June 30, 2024 [44] - Total loans reached $997 million as of June 30, 2024 [58] - Agricultural lending balances represented 12.5% of total loans as of June 30, 2024 [71] Investments and Borrowings - The investment portfolio totaled $445 thousand [41] - Securities totaling $115 million were sold in 1Q24, resulting in a $19.8 million loss [41] - Outstanding BTFP borrowings amounted to $105 million with a rate of 4.85% [55]

Nevada County INVESTOR PRESENTATION UPDATED THROUGH SEPTEMBER 30, 2024 1 Forward Looking Statements Disclaimer The statements contained herein that are not historical facts are forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects on the Company. Such statements involve inherent risks and uncertainties, many of which are difficult to predict and are generally beyond our control. There can be no assurance that future devel ...

Financial Performance - Net income decreased by 389% from $29776 thousand in 2023 to $28619 thousand in 2024[82] - Net interest income increased by 558% from $69794 thousand in 2023 to $73691 thousand in 2024[82] - The net interest margin increased by 170% from 471% in 2023 to 479% in 2024[82] - Return on average assets(ROAA) decreased by 745% from 188% in 2023 to 174% in 2024[82] - Return on average equity(ROAE) decreased by 265% from 234% in 2023 to 172% in 2024[82] Balance Sheet - Total assets increased by 080% from $1610416 thousand in 2023 to $1623326 thousand in 2024[82] - Total deposits increased by 281% from $1333655 thousand in 2023 to $1371101 thousand in 2024[82] - Net loans increased by 598% from $948604 thousand in 2023 to $1005375 thousand in 2024[82] Loan Portfolio - Government guaranteed loans represented approximately 7% of total loans as of December 31 2024[67] - Agricultural lending balances represented 12% of total loans as of December 31 2024[71]

Renewables Portfolio and Growth - AES has a global operating and development portfolio of 66 GW[7] - The company's pipeline includes 12.7 GW of projects[7] - AES' backlog consists of 34.9 GW, with 46% under construction[7,8] - The company expects to add a total of 3.6 GW of new projects in FY 2024[8] Data Center Demand and AES' Position - US data center demand is projected to grow by 35 GW by 2030, driven by GenAI[11] - Over 40% of AES' US backlog is with large technology companies[16] - AES has signed PPAs totaling 5.91 GW with Amazon, Microsoft, Google, and other companies[15] Financial Performance and Targets - AES reaffirmed its 2024 Adjusted EPS guidance of $1.87-$1.97 per share[21] - The company reaffirmed its 2024 Adjusted EBITDA with Tax Attributes guidance of $3.55 billion - $3.95 billion[21] - AES has achieved $2.2 billion in asset sale proceeds for 2023-2024, with a remaining target of $1.3 billion for 2024-2027, totaling $3.5 billion[23,24] - The sale of AES Brasil is expected to generate ~$640 million in proceeds[25]

Company Overview and Strategy - Finward Bancorp has grown from $776 million to $2.1 billion in assets over the last 10 years, representing a 10.3% CAGR[7] - The company aims to build capital and increase returns while positioning for different economic and interest rate outcomes[7] - The company is evaluating opportunities to optimize the balance sheet and improve earnings quality[7] Financial Performance - Total assets were $2.075 billion as of September YTD 2024[11] - Total loans were $1.508 billion as of September YTD 2024[11] - Total deposits were $1.748 billion as of September YTD 2024[11] - Total equity was $160 million as of September YTD 2024[11] - The tax-adjusted net interest margin was 2.67% for the three months ended September 30, 2024[22] Asset Quality and Loan Portfolio - Non-performing loans totaled $13.8 million, representing 0.92% of total loans as of September 30, 2024[48] - The bank originated $70.4 million in new commercial loans during the quarter ended September 30, 2024[39] - Total 1-4 family originations for the quarter ended September 30, 2024, totaled $20.1 million[39]

This presentation contains "forward-looking statements" within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements reflect the current views of the Company's management with respect to, among other things, future events and the Company's financial performance. These statements are often, but not always, made through the use of words or phrases such as "may," "should," "could," "predict," "potential," "believe," "will likely result," "expect," "con ...

Financial Performance & Growth - Total assets increased to $3365 million as of December 31, 2024, a year-over-year growth of 2.5%[26] - Net interest income after provision for credit losses increased 7.5% year-over-year for full year 2024[28] - Deposits reached a record $2690 million as of December 31, 2024, a 3.0% year-over-year increase[32] - From 2019 to 2024, total deposits increased at a CAGR of 15.8%[48] - F&M funded $1423 million in PPP loans over two years, including $538 million in 2021[69] Market Position & Expansion - F&M's total deposits have increased 42.7%, or by $791 million from 2021 to 2024[16] - Deposits within F&M's Ohio markets have increased 45.8%, or by $607 million from 2021 to 2024[16] - Deposits within F&M's Indiana markets have increased 27.6%, or by $145 million from 2021 to 2024[16] - New offices opened in 2023 added $53.9 million of new deposits and $80.5 million in new loans during 2024[32] Digital Transformation & Loan Portfolio - Mobile customers increased by 27.26% in 2024[30] - Approximately 31% of F&M's loan portfolio is subject to reprice in the next 12 months as of December 31, 2024[56]